Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
暂无分享,去创建一个
P. Fenaux | Y. Kwong | K. Ando | R. Cairoli | Y. Miyazaki | U. Platzbecker | V. Santini | A. Zeidan | H. Hou | V. Pullarkat | M. Turgut | O. Rauzy | S. Meers | F. Kiertsman | M. Arnán Sangerman | K. Malek | P. Marques Ramos | Jiaying Lyu | Ming-Chung Wang